Variants cause significant concern all around the globe SQI's menu of diagnostics may not have played a role (Covid-19) in the rearview mirror, but it sure looks like there will be significant adoption sooner than later.
Its hard for any potential new investors to learn much about SQI and all they have to offer, as the Company has chose not to progressively share the story. One would think as a minimum standard, the company would keep an investor presentation available for others to see, but unfortunately has choosen to keep this story tucked well under the radar...(not even an IR firm)....Its running in stealth mode. Next to no awareness anywhere, but especially in the market that would get this story (USA).
While the share price goes up and down some, it means little as this is not yet valued by an informed market of integrity. That can only come with sharing the story and the diverse liquidity that follows. Informing and attracting a following of integrity will take the value setting out of the hands of a few and provide a true market valuation.
Beyond waiting on feedback from the FDA on the first submission, there are two others to be submitted in the weeks ahead. We should hear an update as it relates to Health Canada before the end of this month as well.
Silence is not marketing, sharing our story is.
The Week UKIs China’s Covid-19 pandemic response stalling?Tough restrictions reimposed as Beijing battles coronavirus variants amid concerns about efficacy of home-grown vaccines · An open mind on the ...11 hours ago